bla

Showing 3 posts of 3 posts found.

FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment

April 2, 2024
Research and Development AstraZeneca, Daiichi Sankyo, FDA, Oncology, bla, breast cancer

AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan (Dato-Dxd) has been accepted in …

FDA accepts BLA for Regeneron’s linvoseltamab for Priority Review

February 22, 2024
Medical Communications FDA, Oncology, Regeneron, bla, priority review

Regeneron Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for …

Teva image

FDA accepts Teva asthma drug for review

June 15, 2015
Sales and Marketing AstraZeneca, GlaxoSmithKline’s mepolizumab, Teva, benralizumab, bla, cinquil, reslizumab

Teva’s investigational biologic for the treatment of inadequately controlled asthma in patients with elevated blood eosinophils, Cinquil, has been accepted …

Latest content